Collaborative Research program in Biomedical Innovation Law

The Collaborative Research Programme for Biomedical Innovation Law will focus on innovation inefficiencies on the Life Science Frontiers through 5 concrete interrelated studies complemented by a 6th synergy study. 

The common aim of the 5 concrete studies is to optimize legal concepts into enabling tools that will help to bring novel technologies, research and biomedicine together for radical innovation – thereby providing a much-needed contribution to bridging bio-pharmaceutical innovation gaps, enhancing translational medicine and promoting technology transfer. A 6th overarching policy & synergy study will ensure continuous knowledge and synergy across the 5 concrete studies.

Table of study six: synergy and policy solutions

The 5 concrete studies and the 6th Synergy study aim to demonstrate how legal science methods, that take careful account of interdisciplinary insights and “real world” perspectives, can both generate and contribute to new knowledge about key factors driving pharmaceutical innovation. In addition, such methods will be utilised to examine how innovation incentives that are not depending on patents can be applied, combined, optimized and conceptualized in order to either substitute or complement patent protection in new areas of crucial medical applications.

PI: Timo Minssen